Affiliation: Humboldt University
Christoph F, Weikert S, Wolff I, Schostak M, Tabiti K, Muller M, et al
. Urinary cytokeratin 20 mRNA expression has the potential to predict recurrence in superficial transitional cell carcinoma of the bladder. Cancer Lett. 2007;245:121-6 pubmed
..It helps to categorize patients prior to TUR-B, so that the cystoscopy interval during follow-up may be extended in those with low-risk superficial TCC. ..
Christoph F, Weikert S, Kempkensteffen C, Krause H, Schostak M, Kollermann J, et al
. Promoter hypermethylation profile of kidney cancer with new proapoptotic p53 target genes and clinical implications. Clin Cancer Res. 2006;12:5040-6 pubmed
..Our findings indicate that promoter hypermethylation of APAF-1 and DAPK-1 is a marker of aggressive renal cell carcinoma and provides independent prognostic information on disease outcome. ..
Christoph F, Kempkensteffen C, Weikert S, Krause H, Schostak M, Miller K, et al
. Frequent epigenetic inactivation of p53 target genes in seminomatous and nonseminomatous germ cell tumors. Cancer Lett. 2007;247:137-42 pubmed
..Further studies will be necessary to determine whether the methylation level may be used as marker for risk estimation, especially in clinical stage I disease. ..
Christoph F, Kempkensteffen C, Weikert S, Kollermann J, Krause H, Miller K, et al
. Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer. Br J Cancer. 2006;95:1701-7 pubmed
..In conclusion, demethylating agents effectively retard growth of TCC and RCC cell lines. Methylation level analysis of specific genes has the potential for further tumour characterisation in TCC and RCC. ..
Christoph F, Hinz S, Weikert S, Kempkensteffen C, Schostak M, Miller K, et al
. Comparative promoter methylation analysis of p53 target genes in urogenital cancers. Urol Int. 2008;80:398-404 pubmed publisher
..The different methylation pattern in testicular cancer might represent a different methylotype of this cancer. The extent of promoter methylation may be a promising target for application as a tumor marker in urogenital cancer disease. ..